862
S. H. Kim et al. / Tetrahedron Letters 51 (2010) 860–862
indium powder (228 mg, 2.0 mmol) in THF (1.5 mL) was heated to reflux for
Acknowledgements
30 min. After the usual aqueous workup and column chromatographic
purification process (hexanes/CH2Cl2/EtOAc, 5:1:1) we obtained compound
2a (151 mg, 71%) as a white solid. Other compounds were synthesized similarly
and the spectroscopic data of 2a, 2c, 2f, 2g, and RCM product 3 are as follows.
Compound 2a: 71%; white solid, mp 99–100 °C; IR (film) 3211, 1695, 1615,
This research was supported by Basic Science Research Program
through the National Research Foundation of Korea (NRF) funded
by the Ministry of Education, Science and Technology (2009-
0070633). Spectroscopic data was obtained from the Korea Basic
Science Institute, Gwangju branch.
1469 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.53–2.70 (m, 4H), 5.00–5.07 (m, 4H),
;
5.48–5.62 (m, 2H), 7.38 (dt, J = 7.5 and 0.9 Hz, 1H), 7.44 (td, J = 7.5 and 1.2 Hz,
1H), 7.56 (td, J = 7.5 and 1.2 Hz, 1H), 7.57 (br s, 1H), 7.82 (dq, J = 7.5 and 0.6 Hz,
1H); 13C NMR (CDCl3, 75 MHz) d 42.81, 64.07, 119.65, 121.63, 123.70, 128.07,
131.71, 131.74, 132.10, 149.66, 170.42; ESIMS m/z 236 (M++Na). Anal. Calcd for
C14H15NO: C, 78.84; H, 7.09; N, 6.57. Found: C, 78.92; H, 7.31; N, 6.44.
Compound 2c: 70%; white solid, mp 103–104 °C; IR (film) 3217, 1694, 1621,
References and notes
1. For the general review on indium-mediated reactions, see: (a) Auge, J.; Lubin-
Germain, N.; Uziel, J. Synthesis 2007, 1739–1764; (b) Kargbo, R. B.; Cook, G. R.
Curr. Org. Chem. 2007, 11, 1287–1309; (c) Lee, P. H. Bull. Korean Chem. Soc. 2007,
28, 17–28; (d) Li, C.-J.; Chan, T.-H. Tetrahedron 1999, 55, 11149–11176; (e) Pae,
A. N.; Cho, Y. S. Curr. Org. Chem. 2002, 6, 715–737.
2. (a) Fujiwara, N.; Yamamoto, Y. Tetrahedron Lett. 1998, 39, 4729–4732; (b)
Fujiwara, N.; Yamamoto, Y. J. Org. Chem. 1999, 64, 4095–4101; For diallylation
of benzonitrile with allylindate, see: (c) Jin, S.-J.; Araki, S.; Butsugan, Y. Bull.
Chem. Soc. Jpn. 1993, 66, 1528–1532; For the indium(I) iodide-promoted
1493, 1435 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.51–2.67 (m, 4H), 3.86 (s, 3H),
;
5.00–5.07 (m, 4H), 5.49–5.63 (m, 2H), 7.11 (dd, J = 8.4 and 2.4 Hz, 1H), 7.27 (dd,
J = 8.4 and 0.6 Hz, 1H), 7.30 (d, J = 2.4 Hz, 1H), 7.69 (br s, 1H); 13C NMR (CDCl3,
75 MHz) d 42.87, 55.55, 63.73, 106.28, 119.48, 120.00, 122.53, 131.85, 133.45,
141.89, 159.88, 170,36; ESIMS m/z 266 (M++Na). Anal. Calcd for C15H17NO2: C,
74.05; H, 7.04; N, 5.76. Found: C, 74.40; H, 7.11; N, 5.49.
Compound 2f: 73%; white solid, mp 102–103 °C; IR (film) 3222, 1702, 1607,
1587, 1413 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.74 (d, J = 7.2 Hz, 4H), 4.96–5.06
;
(m, 4H), 5.46–5.60 (m, 2H), 7.38 (dd, J = 7.8 and 4.8 Hz, 1H), 7.77 (br s, 1H), 8.10
(dd, J = 7.8 and 1.5 Hz, 1H), 8.77 (dd, J = 8.1 and 1.5 Hz, 1H); 13C NMR (CDCl3,
75 MHz) d 41.46, 65.36, 119.79, 123.03, 125.99, 131.29, 131.79, 152.64, 168.50,
168.56; ESIMS m/z 237 (M++Na).
allylation of
Lett. 2004, 45, 6875–6877.
a,b-unsaturated nitrile, see: (d) Ranu, B. C.; Das, A. Tetrahedron
3. (a) Kim, S. H.; Lee, H. S.; Kim, K. H.; Kim, J. N. Tetrahedron Lett. 2009, 50, 1696–
1698; (b) Kim, S. H.; Kim, S. H.; Lee, K. Y.; Kim, J. N. Tetrahedron Lett. 2009, 50,
5744–5747; (c) Kim, S. H.; Lee, H. S.; Kim, K. H.; Kim, J. N. Tetrahedron Lett.
2009, 50, 6476–6479.
Compound 2g: 65%; white solid, mp 145–146 °C; IR (film) 3213, 1693, 1620,
1462, 1435, 1383 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.88–3.04 (m, 4H), 4.85–
;
5.01 (m, 4H), 5.33–5.47 (m, 2H), 7.55 (br s, 1H), 7.59–7.68 (m, 2H), 7.87 (d,
J = 8.4 Hz, 1H), 7.94 (d, J = 8.4 Hz, 1H), 7.99–8.02 (m, 1H), 8.08–8.11 (m, 1H);
13C NMR (CDCl3, 75 MHz) d 42.86, 65.73, 119.40, 119.79, 123.68, 126.98,
127.21, 127.46, 129.71, 129.85, 130.77, 131.35, 135.76, 146.43, 170.48; ESIMS
m/z 286 (M++Na).
4. For the biological activities of isoindolone derivatives, see: (a) Riedinger, C.;
Endicott, J. A.; Kemp, S. J.; Smyth, L. A.; Watson, A.; Valeur, E.; Golding, B. T.;
Griffin, R. J.; Hardcastle, I. R.; Noble, M. E.; McDonnell, J. M. J. Am. Chem. Soc.
2008, 130, 16038–16044; (b) Hudkins, R. L.; Johnson, N. W.; Angeles, T. S.;
Gessner, G. W.; Mallamo, J. P. J. Med. Chem. 2007, 50, 433–441; (c) Jitsuoka, M.;
Tsukahara, D.; Ito, S.; Tanaka, T.; Takenaga, N.; Tokita, S.; Sato, N. Bioorg. Med.
Chem. Lett. 2008, 18, 5101–5106; (d) Comins, D. L.; Schilling, S.; Zhang, Y. Org.
Lett. 2005, 7, 95–98. and further references cited therein; (e) Fardis, M.; Jin, H.;
Jabri, S.; Cai, R. Z.; Mish, M.; Tsiang, M.; Kim, C. U. Bioorg. Med. Chem. Lett. 2006,
16, 4031–4035; (f) Wrobel, J.; Dietrich, A.; Woolson, S. A.; Millen, J.; McCaleb,
M.; Harrison, M. C.; Hohman, T. C.; Sredy, J.; Sullivan, D. J. Med. Chem. 1992, 35,
4613–4627.
Compound 3: 88%; white solid, mp 160–161 °C; IR (film) 3211, 1693, 1620,
1462, 1383 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.86 (d, J = 16.2 Hz, 2H), 3.28 (d,
;
J = 16.2 Hz, 2H), 6.00–6.06 (m, 2H), 7.54–7.64 (m, 2H), 7.74–7.77 (m, 1H), 7.87
(d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.98–8.01 (m, 1H), 8.07 (br s, 1H); 13C
NMR (CDCl3, 125 MHz) d 45.74, 66.96, 119.66, 123.33, 126.92, 127.00, 127.28,
128.94, 129.00, 129.26, 129.65, 135.80, 148.99, 170.10; ESIMS m/z 258
(M++Na). Anal. Calcd for C16H13NO: C, 81.68; H, 5.57; N, 5.95. Found: C,
81.82; H, 5.63; N, 5.69.
5. For the synthesis of isoindolone derivatives, see: (a Murai, M.; Miki, K.; Ohe, K.
J. Org. Chem. 2008, 73, 9174–9176; (b) Salcedo, A.; Neuville, L.; Zhu, J. J. Org.
Chem. 2008, 73, 3600–3603; (c) Campbell, J. B.; Dedinas, R. F.; Trumbower-
Walsh, S. A. J. Org. Chem. 1996, 61, 6205–6211; (d) He, Z.; Yudin, A. K. Org. Lett.
2006, 8, 5829–5832; (e) Kobayashi, K.; Hase, M.; Hashimoto, K.; Fujita, S.;
Tanmatsu, M.; Morikawa, O.; Konishi, H. Synthesis 2006, 2493–2496; (f) Enders,
D.; Braig, V.; Raabe, G. Can. J. Chem. 2001, 79, 1528–1535; (g) Sun, C.; Xu, B. J.
Org. Chem. 2008, 73, 7361–7364; (h) Deville, J. P.; Behar, V. Org. Lett. 2002, 4,
1403–1405; (i) Araki, S.; Shimizu, T.; Johar, P. S.; Jin, S.-J.; Butsugan, Y. J. Org.
Chem. 1991, 56, 2538–2542.
6. For the synthesis of polycyclic- and spiro-isoindolone derivatives, see: (a
Medimagh, R.; Marque, S.; Prim, D.; Marrot, J.; Chatti, S. Org. Lett. 2009, 11,
1817–1820; (b) Osante, I.; Lete, E.; Sotomayor, N. Tetrahedron Lett. 2004, 45,
1253–1256; (c) Bahajaj, A. A.; Vernon, J. M.; Wilson, G. D. Tetrahedron 2004, 60,
1247–1253; (d) Kang, S. W.; Kim, S. H. Bull. Korean Chem. Soc. 2006, 27, 153–
154; (e) Kang, S. W.; Heo, E. Y.; Jun, J. G.; Kim, S. H. Bull. Korean Chem. Soc. 2004,
25, 1924–1928; (f) Majumdar, K. C.; Das, T. K.; Jana, M. Synth. Commun. 2005,
35, 1961–1969; (g) Bertus, P.; Menant, C.; Tanguy, C.; Szymoniak, J. Org. Lett.
2008, 10, 777–780; (h) Bertus, P.; Szymoniak, J. J. Org. Chem. 2003, 68, 7133–
7136.
9. Starting material 1a was purchased from the commercial source. Other
compounds (1b–g) were synthesized from the corresponding bromides or
chlorides via the Rosenmund-von Braun reaction with CuCN in DMF as
reported, see: (a) Powers, J. J.; Favor, D. A.; Rankin, T.; Sharma, R.; Pandit, C.;
Jeganathan, A.; Maiti, S. N. Tetrahedron Lett. 2009, 50, 1267–1269. (b) Wang, D.;
Kuang, L.; Li, Z.; Ding, K. Synlett 2008, 69–72. The spectroscopic data of
unknown compounds 1b and 1g are as follows.
Compound 1b: 85%; white solid, mp 65–66°C; IR (film) 2228, 1711, 1604,
1436 cmÀ1 1H NMR (CDCl3, 300 MHz) d 2.46 (s, 3H), 3.98 (s, 3H), 7.47 (ddd,
;
J = 8.1, 1.8, and 0.6 Hz, 1H), 7.60–7.61 (m, 1H), 8.03 (d, J = 8.1 Hz, 1H); 13C NMR
(CDCl3, 75 MHz) d 21.18, 52.61, 112.81, 117.64, 129.57, 131.14, 133.16, 135.23,
143.79, 164.51; ESIMS m/z 198 (M++Na).
Compound 1g: 85%; white solid, mp 109–110°C; IR (film) 2222, 1730, 1619,
1467 cmÀ1 1H NMR (CDCl3, 300 MHz) d 4.06 (s, 3H), 7.66–7.76 (m, 2H), 7.91–
;
7.95 (m, 1H), 8.07 (s, 2H), 8.39–8.42 (m, 1H); 13C NMR (CDCl3, 75 MHz) d 52.86,
111.25, 115.73, 125.35, 126.40, 128.34, 129.19 (2C), 131.99, 132.61 (2C),
134.30, 164.79; ESIMS m/z 234 (M++Na).
10. For the mechanistic study of In-mediated allylation, see: (a) Isaac, M. B.; Chan,
T.-H. Tetrahedron Lett. 1995, 36, 8957–8960; (b) Tan, K.-T.; Chng, S.-S.; Cheng,
H.-S.; Loh, T.-P. J. Am. Chem. Soc. 2003, 125, 2958–2963; (c) Loh, T.-P.; Tan, K.-T.;
Hu, Q.-Y. Tetrahedron Lett. 2001, 42, 8705–8708; (d) Loh, T.-P.; Tan, K.-T.; Yang,
J.-Y.; Xiang, C.-L. Tetrahedron Lett. 2001, 42, 8701–8703.
7. Sun, X.-W.; Liu, M.; Xu, M.-H.; Lin, G.-Q. Org. Lett. 2008, 10, 1259–1262.
8. Typical procedure for the synthesis of compound 2a:
A stirred mixture of
compound 1a (175 mg, 1.0 mmol), allyl bromide (484 mg, 4.0 mmol), and